A5057646591- Glioma Diagnosis and Treatment
- Cancer, Hypoxia, and Metabolism
- Neurofibromatosis and Schwannoma Cases
- Brain Metastases and Treatment
- Radiomics and Machine Learning in Medical Imaging
- Multiple Sclerosis Research Studies
- Neuroblastoma Research and Treatments
- Immunotherapy and Immune Responses
- Immune cells in cancer
- Meningioma and schwannoma management
- Neuroendocrine Tumor Research Advances
- Cancer Genomics and Diagnostics
- Sarcoma Diagnosis and Treatment
- Cancer Treatment and Pharmacology
- Extracellular vesicles in disease
- Phagocytosis and Immune Regulation
- Medical Imaging Techniques and Applications
- Cancer Immunotherapy and Biomarkers
- Cancer Research and Treatments
- Nanoplatforms for cancer theranostics
- Systemic Lupus Erythematosus Research
- MRI in cancer diagnosis
- Peripheral Neuropathies and Disorders
- Chromatin Remodeling and Cancer
- interferon and immune responses
Fondazione IRCCS Istituto Neurologico Carlo Besta
2016-2025
Istituti di Ricovero e Cura a Carattere Scientifico
2016-2022
Centre National de la Recherche Scientifique
2021
Assistance Publique – Hôpitaux de Paris
2021
Sorbonne Université
2021
Institut du Cerveau
2021
Institut Gustave Roussy
2021
Inserm
2021
Université Paris-Saclay
2021
GTx (United States)
2019
Abstract Purpose: Oncogenic fusions consisting of fibroblast growth factor receptor (FGFR) and TACC are present in a subgroup glioblastoma (GBM) other human cancers have been proposed as new therapeutic targets. We analyzed frequency molecular features FGFR–TACC explored the efficacy inhibiting FGFR kinase GBM grade II III glioma. Experimental Design: Overall, 795 gliomas (584 GBM, 85 grades with wild-type 126 IDH1/2 mutation) were screened for breakpoints associated profile. also expression...
Abstract Purpose: Sodium fluorescein is a dye that, intravenously injected, selectively accumulates in high-grade glioma (HGG) tissue through damaged blood–brain barrier. In this article, the final results of multicentric prospective phase II trial (FLUOGLIO) on fluorescein-guided HGG resection dedicated filter surgical microscope were reported. Methods: Patients with suspected HGGs considered suitable for removal eligible to participate trial. Fluorescein was injected at dose 5 10 mg/kg....
Neurofibromatosis type 1 (NF1), a common genetic disorder with birth incidence of 1:2,000–3,000, is characterized by highly variable clinical presentation. To date, only two clinically relevant intragenic genotype-phenotype correlations have been reported for NF1 missense mutations affecting p.Arg1809 and single amino acid deletion p.Met922del. Both variants predispose to distinct mild phenotype neither externally visible cutaneous/plexiform neurofibromas nor other tumors. Here, we report...
Abstract Background Depatuxizumab mafodotin (Depatux-M) is a tumor-specific antibody–drug conjugate consisting of an antibody (ABT-806) directed against activated epidermal growth factor receptor (EGFR) and the toxin monomethylauristatin-F. We investigated Depatux-M in combination with temozolomide or as single agent randomized controlled phase II trial recurrent EGFR amplified glioblastoma. Methods Eligible were patients centrally confirmed glioblastoma at first recurrence after...
Although physical rehabilitation is commonly administered to MS patients, its efficacy has not been established.We assessed the of an inpatient program on impairment, disability, and quality life patients with a randomized, single-blind, controlled trial.Fifty ambulatory were assigned 3 weeks (study treatment) or exercises performed at home (control treatment). Patients evaluated baseline 3, 9, 15 by blinded examining physician.No changes in impairment occurred either group, as measured...
Object Fluorescein, a dye that is widely used as fluorescent tracer, accumulates in cerebral areas where the blood-brain barrier damaged. This quality makes it an ideal for intraoperative visualization of high-grade gliomas (HGGs). The authors report their experience with new fluorescein-guided technique resection HGGs using dedicated filter on surgical microscope. Methods initiated prospective Phase II trial (FLUOGLIO) September 2011 objective evaluating safety surgery and obtaining...
Abstract Purpose: Recent data suggest that methylation of the DNA repair gene O6-methylguanine methyltransferase (MGMT), by increasing chemosensitivity glioblastoma multiforme, is significantly associated with improved prognosis. Results in contradiction these findings, however, are present literature and clinical genetic context framing MGMT poorly characterized. Experimental Design: To address issues, we have investigated status, magnetic resonance imaging characteristics, relevant...
Hereditary spastic paraplegias are a heterogeneous group of neurodegenerative disorders, clinically classified in pure and complex forms. Genetically, more than 70 different forms have been characterized. A subgroup complicate recessive has distinguished for the presence thin corpus callosum white matter lesions at brain imaging. This includes several genetic entities, but most cases caused by mutations KIAA1840 (SPG11) ZFYVE26 genes (SPG15). We studied cohort 61 consecutive patients with...
Reliable biomarkers are needed to avoid diagnostic delay and its devastating effects in patients with primary central nervous system (CNS) lymphoma (PCNSL). We analysed the discriminating sensitivity specificity of myeloid differentiation response (88) (MYD88) L265P mutation (mut-MYD88) interleukin-10 (IL-10) cerebrospinal fluid (CSF) both newly diagnosed (n = 36) relapsed 27) PCNSL 162 controls (118 CNS disorders 44 extra-CNS lymphomas). The concordance MYD88 mutational status between...
Abstract Glioblastoma multiforme (GBM) is an extremely malignant brain tumor. To identify new genomic alterations in GBM, DNA of tumor tissue/explants from 55 individuals and 6 GBM cell lines were examined using single nucleotide polymorphism microarray (SNP-Chip). Further gene expression analysis relied on additional 56 samples. SNP-Chip results validated several techniques, including quantitative PCR (Q-PCR), sequencing, a combination Q-PCR detection microsatellite markers for loss...
// Maria Carmela Speranza 1,3 , Véronique Frattini Federica Pisati Dimos Kapetis 2 Paola Porrati 1 Marica Eoli Serena Pellegatta and Gaetano Finocchiaro Unit of Molecular Neuro-Oncology, Fondazione I.R.C.C.S. Istituto Neurologico C. Besta, Milan, Italy Bioinformatics, 3 Dept Experimental Oncology, Campus IFOM-IEO, Correspondence: Finocchiaro, email: Keywords : miR-145, NEDD9, invasion, progression, glioma, glioblastoma Received July 31, 2012, Accepted August 04, Published 05, 2012...
Few prospective studies have assessed the role of bevacizumab and included a control arm with standard treatments for recurrent glioblastoma. We conducted noncomparative phase II trial (AVAREG) to examine efficacy or fotemustine in this setting.Eligible patients were randomized 2:1 receive (10 mg/kg every 2 weeks) (75 mg/m(2) on days 1, 8, 15, then 100 3 weeks after 35-day interval). The primary endpoint was 6-month overall survival (OS) rate (OS-6). No formal comparison made between...
Patients with glioblastoma (GBM) have a dramatically poor prognosis. The recent REGOMA trial suggested an overall survival (OS) benefit of regorafenib in recurrent GBM patients. Considering the extreme genetic heterogeneity GBMs, we aimed to identify molecular biomarkers predictive differential response drug.Total RNA was extracted from tumor samples patients enrolled trial. Genome-wide transcriptome and micro (mi)RNA profiles were associated patients' OS progression-free survival.In first...
Actionable fibroblast growth factor receptor 3 (FGFR3)-transforming acidic coiled-coil protein fusions (F3T3) are found in approximately 3% of gliomas, but their characteristics and prognostic significance still poorly defined. Our goal was to characterize the clinical, radiological, molecular profile F3T3 positive diffuse gliomas.We screened fusion by real-time (RT)-PCR FGFR3 immunohistochemistry a large series characterized for main genetic alterations, histology, clinical evolution. We...
Recurrent glioblastomas (GBs) are highly aggressive tumors associated with a 6–8 mo survival rate. In this study, we evaluated the possible benefits of an immunotherapeutic strategy based on mature dendritic cells (DCs) loaded autologous tumor-cell lysates in 15 patients affected by recurrent GB. The median progression-free (PFS) patient cohort was 4.4 mo, and overall (OS) 8.0 mo. Patients small at time first vaccination (< 20 cm3; n = 8) had significantly longer PFS OS than other (6.0 vs....
In a two-stage phase II study, 24 patients with first diagnosis of glioblastoma (GBM) were treated dendritic cell (DC) immunotherapy associated to standard radiochemotherapy temozolomide (TMZ) followed by adjuvant TMZ. Three intradermal injections mature DC loaded autologous GBM lysate administered before TMZ, while 4 performed during According Simon design, proceed the second stage progression-free survival (PFS) 12 months after surgery was expected in at least 8 cases enrolled stage....
The efficacy of dexamethasone (DX) and methylprednisolone (MP) at high (HD) low (LD) dose in acute multiple sclerosis (MS) relapses was evaluated by a double-blind trial 31 patients followed for 1 year. DX HDMP were similarly efficacious promoting recovery, while LDMP ineffective the short-term outcome an early clinical reactivation. different outcomes seem to be related immunomodulating effects, mainly on cerebrospinal fluid (CSF) IgG synthesis peripheral blood CSF CD4+ lymphocyte subsets.